
Kluwer Patent Blog

Elan Pharma v. Ethypharm, District Court Paris (Tribunal de Grande Instance Paris), 21 December 2012

Emmanuel Gougé (Pinsent Masons) · Thursday, May 2nd, 2013

The Paris District Court clarified its interpretation of Article 123 EPC regarding disclaimer allowability and allowed a disclaimer restoring novelty of a patent.

Click [here](#) for the full text of this case.

A summary of this case will be posted on <http://www.Kluweriplaw.com> .

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2022 Future Ready Lawyer survey** showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how **Kluwer IP Law** can support you.

79% of the lawyers think that the importance of legal technology will increase for next year.

Drive change with Kluwer IP Law.

The master resource for Intellectual Property rights and registration.



2022 SURVEY REPORT
The Wolters Kluwer Future Ready Lawyer
Leading change



This entry was posted on Thursday, May 2nd, 2013 at 12:40 pm and is filed under [Case Law](#), [Disclaimer](#), [France](#), [Inventive step](#), [Novelty](#), [Pharma](#)

You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.